Toll-like receptors, immunoproteasome and regulatory T cells in children with Henoch–Schönlein purpura and primary IgA nephropathy

Davin JC (2011) Henoch-Schonlein purpura nephritis: pathophysiology, treatment, and future strategy. Clin J Am Soc Nephrol 6:679–689

Coppo R (2008) Pediatric IgA nephropathy: clinical and therapeutic perspectives. Semin Nephrol 28:18–26

Davin JC, Ten Berge IJ, Weening JJ (2001) What is the difference between IgA nephropathy and Henoch-Schönlein purpura nephritis? Kidney Int 59:823–834

Calvo-Río V, Loricera J, Martín L, Ortiz-Sanjuán F, Alvarez L, González-Vela MC, González-Lamuño D, Mata C, Gortázar P, Rueda-Gotor J, Arias M, Peiró E, Martínez-Taboada VM, González-Gay MA, Blanco R (2013) Henoch-Schönlein purpura nephritis and IgA nephropathy: a comparative clinical study. Clin Exp Rheumatol 31:S45–S51

Bogdanovic R (2009) Henoch-Schönlein purpura nephritis in children: Risk factors, prevention and treatment. Acta Paediatr 98:1882–1889

Coppo R, Mazzucco G, Cagnoli L, Lupo A, Schena FP (1997) Longterm prognosis of Henoch-Schönlein nephritis in adults and children. Italian Group of Renal Immunopathology Collaborative Study on Henoch-Schönlein purpura. Nephrol Dial Transplant 12:2277–2283

Edström Halling S, Söderberg MP, Berg UB (2012) Predictors of outcome in paediatric IgA nephropathy with regard to clinical and histopathological variables (Oxford classification). Nephrol Dial Transplant 27:715–722

Shima Y, Nakanishi K, Hama T, Mukaiyama H, Togawa H, Sako M, Kaito H, Nozu K, Tanaka R, Iijima K, Yoshikawa N (2013) Spontaneous remission in children with IgA nephropathy. Pediatr Nephrol 28:71–76

Novak J, Julian BA, Mestecky J, Renfrow MB (2012) Glycosylation of IgA1 and pathogenesis of IgA nephropathy. Semin Immunopathol 34:365–382

Lau KK, Wyatt RJ, Moldoveanu Z, Tomana M, Julian BA, Hogg RJ, Lee JY, Huang WQ, Mestecky J, Novak J (2007) Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schönlein purpura. Pediatr Nephrol 22:2067–2072

Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, Chathan WW, Suzuki Y, Wyatt RJ, Moldoveanu Z, Lee JY, Robinson J, Tomana M, Tomino Y, Mestecky J, Novak J (2009) Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 119:1668–1677

Wyatt RJ, Julian BA (2013) IgA nephropathy. N Engl J Med 368:2402–2414

Coppo R, Amore A, Peruzzi L, Vergano L, Camilla R (2010) Innate immunity and IgA nephropathy. J Nephrol 23:626–632

Rigante D, Castellazzi L, Bosco A, Esposito S (2013) Is there a crossroad between infections, genetics, and Henoch-Schönlein purpura? Autoimmun Rev 12:1016–1021

Medzhitov R (2007) Recognition of microorganisms and activation of the immune response. Nature 449:819–826

Janeway CA Jr, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20:197–216

Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124:783–801

Beutler BA (2009) TLRs and innate immunity. Blood 113:1399–1407

Rock KL, York IA, Saric T (2002) Protein degradation and generation of MHC class I-presented peptides. Adv Immunol 80:1–70

Macagno A, Kuehn L, de Giuli R, Groettrup M (2001) Pronounced up-regulation of the PA28alpha/β proteasome regulator but little increase in the steady state. Content of immunoproteasome during dendritic cell maturation. Eur J Immunol 31:3271–3280

Pedruzzi LM, Stockler-Pinto MB, Leite M Jr, Mafra D (2012) Nrf2-keap1 system versus NF-κB: the good and the evil in chronic kidney disease? Biochimie 94:2461–2466

Sakaguchi S, Wing K, Miyara M (2007) Regulatory T cells—a brief history and perspective. Eur J Immunol 37 [Suppl 1]:S116–S123

Beyer M, Schultze JL (2011) Plasticity of Treg cells: is reprogramming of Treg cells possible in the presence of FOXP3? Int Immunopharmacol 11:555–560

Turner JE, Paust HJ, Steinmetz OM, Panzer U (2010) The Th17 immune response in renal inflammation. Kidney Int 77:1070–1075

Coarthay A (2009) How do regulatory T cells work? Scand J Immunol 70:326–366

Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, Buoncompagni A, Lazar C, Bilge I, Uziel Y, Rigante D, Cantarini L, Hilario MO, Silva CA, Alegria M, Norambuena X, Belot A, Berkun Y, Estrella AI, Olivieri AN, Alpigiani MG, Rumba I, Sztajnbok F, Tambic-Bukovac L, Breda L, Al-Mayouf S, Mihaylova D, Chsnyk V, Sengler C, Klein-Gitelman M, Djeddi D, Nuno L, Pruunsild C, Brunner J, Kondi A, Pagava K, Pederzoli S, Ruperto N (2010) EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara, 2008. II. Final classification criteria. Ann Rheum Dis 69:798–806

Schwartz GJ, Work DF (2009) Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 4:1832–1843

Coppo R, Camilla R, Amore A, Peruzzi L, Daprà V, Loiacono E, Vatrano S, Rollino C, Sepe V, Rampino T, Dal Canton A (2010) Toll-like receptor 4 expression is increased in circulating mononuclear cells of patients with immunoglobulin A nephropathy. Clin Exp Immunol 159:73–81

Coppo R, Camilla R, Alfarano A, Balegno S, Mancuso D, Peruzzi L, Amore A, Dal Canton A, Sepe V, Tovo P (2009) Upregulation of the immunoproteasome in peripheral blood mononuclear cells of patients with IgA nephropathy. Kidney Int 75:536–541

Lin FJ, Jiang GR, Shan JP, Zhu C, Zou J, Wu XR (2012) Imbalance of regulatory T cells to Th17 cells in IgA nephropathy. Scand J Clin Lab Invest 72:221–229

Jung YO, Cho ML, Lee SY, Oh HJ, Park JS, Park MK, Park MJ, Ju JH, Kim SI, Kim HY, Park SH, Min JK (2009) Synergism of toll-like receptor 2 (TLR2), TLR4, and TLR6ligation on the production of tumor necrosis factor (TNF)-alpha in a spontaneous arthritis animal model of interleukin (IL)-1 receptor antagonist-deficient mice. Immunol Lett 123:138–143

Shirey KA, Lai W, Scott AJ, Lipsky M, Mistry P, Pletneva LM, Karp CL, McAlees J, Gioannini TL, Weiss J, Chen WH, Ernst RK, Rossignol DP, Gusovsky F, Blanco JC, Vogel SN (2013) The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature 497:498–502

Mersmann J, Iskandar F, Latsch K, Habeck K, Sprunck V, Zimmermann R, Schumann RR, Zacharowski K, Koch A (2013) Attenuation of myocardial injury by HMGB1 blockade during ischemia/reperfusion is toll-like receptor 2-dependent. Mediators Inflamm 2013:174168

Savva A, Roger T (2013) Targeting Toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases. Front Immunol 18:4–387

Niewerth D, Franke NE, Jansen G, Assaraf YG, van Meerloo J, Kirk CJ, Degenhardt J, Anderl J, Schimmer AD, Zweegman S, de Haas V, Horton TM, Kaspers GJ, Cloos J (2013) Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors. Haematologica 98:1896–1904